Stock Report

Download full stock data and analysis for free Last Updated: 04-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Xenon Pharmaceuticals (XENE) Key Ratios

Stock Card factsheet share-fund-plan-icon

$60.40

up-down-arrow $0.24 (0.40%)

As on 03-Sep-2026 16:00EDT

Market cap

info icon

$5,809 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

4.8

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -- -7.36 -25.26
EBIT -- -- 3.41 -32.03 -225.20
Net Profit -8.24 -30.73 -47.07 -179.33 -237.58
EPS 5.08 -3.62 -34.29 -55.01 -201.69
Book Value -- -- -23.78 -12.58 9.55
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info -4,598.59-2,131.98---4,598.59--
Net Margin info ---683.26------
Return on equity info -33.91-28.66-44.86-51.76-27.85
Return on Capital info -33.49-28.28---51.11-27.52
Return on Assets info -28.89-25.26-27.75-38.87-26.58
Debt to Equity (x) info ----0.000.010.01

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
--
-51.11
-27.52
-21.83
-19.43
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-44.86

Lower than Peers by 28.88

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
-44.86
-51.76
-27.85
-22.12
-19.72
Peer Median
-15.98
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-27.75

Lower than Peers by 15.90

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
-27.75
-38.87
-26.58
-21.22
-18.91
Peer Median
-11.85
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

--

--

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
--
-4,598.59
--
--
-1,368.91
Peer Median
-27.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

--

--

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
--
-4,612.13
--
--
-941.10
Peer Median
-32.69
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

--

--

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
--
--
--
-1.00
-0.49
Peer Median
33.97
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

3.41

Higher than Peers by 28.67

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
3.41
-44.66
-11.38
-65.75
-63.49
Peer Median
-25.26
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-47.07

Lower than Peers by 25.50

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
-47.07
-47.62
-28.48
-45.48
-58.94
Peer Median
-21.58
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-34.29

Lower than Peers by 28.11

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
-34.29
-0.46
-0.15
-0.37
0.00
Peer Median
-6.17
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

55.33

Higher than Peers by 58.22

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
55.33
--
--
--
--
Peer Median
-2.89
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
--
0.01
0.01
0.01
0.01
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.00

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
0.00
0.00
0.00
0.00
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

21.02

Higher than Peers by 11.91

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
21.02
13.42
17.85
23.65
26.44
Peer Median
9.11
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

21.02

Higher than Peers by 11.91

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
21.02
--
--
23.65
26.49
Peer Median
9.11
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

--

--

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
--
--
--
--
-23.43
Peer Median
0.72
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

--

--

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
--
18.28
--
--
10.45
Peer Median
22.75
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

--

--

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
--
0.01
--
--
0.01
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
--
69.15
--
--
72.61
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
--
--
0.00
-1.07
-6.48
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
--
643.10
975.05
18.63
21.26
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
--
--
--
--
44.87
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
--
-10.27
-13.11
-17.67
-20.65
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

4.83

No difference

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
4.83
6.11
4.07
3.47
3.59
Peer Median
4.83
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

34.16

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
34.16
-8.80
-10.41
-12.33
-15.74
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

5,809

Higher than Peers by 5,593

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Xenon Pharmaceuticals (XENE)
5,809
--
--
--
--
Peer Median
217
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...